333 related articles for article (PubMed ID: 36423966)
1. P2Y
Andò G; De Santis GA; Greco A; Pistelli L; Francaviglia B; Capodanno D; De Caterina R; Capranzano P
JACC Cardiovasc Interv; 2022 Nov; 15(22):2239-2249. PubMed ID: 36423966
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials.
Garg A; Rout A; Sharma A; Sargsyan D; Beavers T; Tantry U; Gurbel P; Rao SV; Kostis JB; Cohen M
Prog Cardiovasc Dis; 2020; 63(3):243-248. PubMed ID: 32247786
[TBL] [Abstract][Full Text] [Related]
3. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.
Giacoppo D; Matsuda Y; Fovino LN; D'Amico G; Gargiulo G; Byrne RA; Capodanno D; Valgimigli M; Mehran R; Tarantini G
Eur Heart J; 2021 Jan; 42(4):308-319. PubMed ID: 33284979
[TBL] [Abstract][Full Text] [Related]
4. P2Y
Gragnano F; Mehran R; Branca M; Franzone A; Baber U; Jang Y; Kimura T; Hahn JY; Zhao Q; Windecker S; Gibson CM; Kim BK; Watanabe H; Song YB; Zhu Y; Vranckx P; Mehta S; Hong SJ; Ando K; Gwon HC; Calabrò P; Serruys PW; Dangas GD; McFadden EP; Angiolillo DJ; Heg D; Valgimigli M;
J Am Coll Cardiol; 2023 Feb; 81(6):537-552. PubMed ID: 36754514
[TBL] [Abstract][Full Text] [Related]
5. Preferred monotherapy after short-term dual antiplatelet therapy: Systematic review and network meta-analysis of randomized trials.
Shoji S; Kuno T; Ueyama H; Takagi H; Briasoulis A; Kim HS; Koo BK; Kang J; Watanabe H; Kimura T; Kohsaka S
J Cardiol; 2024 May; 83(5):338-347. PubMed ID: 37562542
[TBL] [Abstract][Full Text] [Related]
6. Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial.
Choi KH; Park YH; Song YB; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Oh JH; Chun WJ; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Gwon HC; Hahn JY;
JAMA Cardiol; 2022 Nov; 7(11):1100-1108. PubMed ID: 36169938
[TBL] [Abstract][Full Text] [Related]
7. Effect of P2Y12 inhibitor monotherapy versus dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: systematic review and meta-analysis.
Wu XT; He RR; Liang SZ; Ye GY; Ding SB
Minerva Med; 2020 Apr; 111(2):173-180. PubMed ID: 32338843
[TBL] [Abstract][Full Text] [Related]
8. Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention.
Shin ES; Her AY; Kim B; Hahn JY; Song YB; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
J Korean Med Sci; 2023 Nov; 38(45):e383. PubMed ID: 37987108
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of dual antiplatelet therapy after percutaneous coronary drug-eluting stenting: A network meta-analysis.
Luo L; Wang S; Tang K; Yang X; Wu J; Wang D; Xu L; Feng T; Li D; Ran J; Li D; Zhang L; Zhao D
Medicine (Baltimore); 2022 Oct; 101(42):e31158. PubMed ID: 36281144
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
Song YB; Oh SK; Oh JH; Im ES; Cho DK; Cho BR; Lee JY; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; Hahn JY
Am Heart J; 2018 Mar; 197():77-84. PubMed ID: 29447787
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis.
Nicolas J; Dangas G; Chiarito M; Pivato CA; Spirito A; Cao D; Giustino G; Beerkens F; Camaj A; Vogel B; Sartori S; Yamamoto K; Kimura T; Kim BK; Baber U; Mehran R
Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):240-250. PubMed ID: 36564015
[TBL] [Abstract][Full Text] [Related]
12. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
[TBL] [Abstract][Full Text] [Related]
13. P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial.
Min PK; Kang TS; Cho YH; Cheong SS; Kim BK; Kwon SW; Park WJ; Lee JH; Kim W; Lee WS; Yoon YW; Lee BK; Kwon HM; Hong BK;
JAMA Netw Open; 2024 Mar; 7(3):e240877. PubMed ID: 38451525
[TBL] [Abstract][Full Text] [Related]
14. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis.
Khan SU; Singh M; Valavoor S; Khan MU; Lone AN; Khan MZ; Khan MS; Mani P; Kapadia SR; Michos ED; Stone GW; Kalra A; Bhatt DL
Circulation; 2020 Oct; 142(15):1425-1436. PubMed ID: 32795096
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation: A Systematic Review and Network Meta-Analysis.
Xu Y; Shen Y; Chen D; Zhao P; Jiang J
J Interv Cardiol; 2021; 2021():9934535. PubMed ID: 34035674
[TBL] [Abstract][Full Text] [Related]
16. P2Y12 inhibitor monotherapy versus aspirin monotherapy after short-term dual antiplatelet therapy for percutaneous coronary intervention: Insights from a network meta-analysis of randomized trials.
Kuno T; Ueyama H; Takagi H; Bangalore S
Am Heart J; 2020 Sep; 227():82-90. PubMed ID: 32693196
[TBL] [Abstract][Full Text] [Related]
17. P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis.
Ho AC; Egolum U; Parker S; Dimmel J; Hawkins A; Ling H
Clin Drug Investig; 2020 Sep; 40(9):799-808. PubMed ID: 32661914
[TBL] [Abstract][Full Text] [Related]
18. P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 patients.
Bianco M; Careggio A; Destefanis P; Luciano A; Perrelli MG; Quadri G; Rossini R; Campo G; Vizzari G; D'Ascenzo F; Anselmino M; Biondi-Zoccai G; Ibáñez B; Montagna L; Varbella F; Cerrato E
Eur Heart J Cardiovasc Pharmacother; 2021 May; 7(3):196-205. PubMed ID: 32544220
[TBL] [Abstract][Full Text] [Related]
19. Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials.
Montalto C; Costa F; Leonardi S; Micari A; Oreglia JA; Vranckx P; Capodanno D; Ten Berg J; Lopes RD; Valgimigli M
Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):220-230. PubMed ID: 36427063
[TBL] [Abstract][Full Text] [Related]
20. Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
Feng WH; Chang YC; Lin YH; Chen HL; Chang HM; Chu CS
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
